🏢 Company Intelligence
What They Do
Sangamo Therapeutics is a clinical-stage genomic medicines company developing engineered cell and gene therapies using its proprietary zinc finger (ZF) technology platform, which enables precise DNA targeting for gene editing, gene regulation, and cell therapy applications. Its pipeline focuses on neurological diseases, with a key asset being an intrathecally-delivered AAV capsid for CNS gene therapy targeting conditions like Fabry disease, prion disease, and chronic neuropathic pain.
Why FSI Keeps Surfacing This Company
FSI's pipeline repeatedly flags SGMO due to its deep zinc finger IP portfolio and a string of high-value licensing deals with Pfizer, Novartis, Genentech, Astellas, and Eli Lilly leveraging its STAC-BBB capsid and epigenetic regulation technologies. Recent partnership announcements and milestone payments, combined with extreme price volatility and elevated trading volume, continue to push it into signal detection thresholds.
Recent Developments
In 2024-2025, Sangamo secured a capsid licensing deal with Eli Lilly worth up to $1.4B plus royalties for CNS-targeted gene therapy delivery, and announced additional Genentech and Astellas collaborations expanding its neurology and epigenetic regulator franchises. The company also reported positive long-term data from its hemophilia A gene therapy partnership and is advancing ST-503 for chronic pain into clinical trials.
Key Risks
Sangamo faces severe balance sheet pressure with a sub-$1 share price, going concern warnings, and reliance on partner milestone payments to fund operations, raising dilution and Nasdaq delisting risks. It also competes against better-capitalized CRISPR and AAV gene therapy players (CRSP, BEAM, NTLA, RGNX), and its zinc finger platform has yet to produce a wholly-owned approved product.
🔗 Technology Domains
👁️
Showcase mode.
The top 2 companies per domain will remain free. Deeper features below — AI corpus interrogation, swap reasoning, Telegram alerts — will require Premium (£70/month).
Request early access →
🚀 Premium Features — Coming Soon
Premium subscribers will get AI interrogation of the full 56,000+ article corpus, real-time Telegram alerts when this company is flagged, swap proposals with full reasoning, and the complete signal history for SGMO. Subscriptions launching soon.
Request Early Access →
Not investment advice. Company intelligence is derived from publicly available data sources. It does not constitute personalised investment advice or a recommendation to buy, sell, or hold SGMO. Capital at risk. Always seek independent financial advice.